Navigation Links
Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
Date:2/29/2008

SOMERSET, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it will host a conference call and Webcast at 11 a.m. EST on Friday, March 7. During the call, Kuslima Shogen, Alfacell's chief executive officer, and Lawrence A. Kenyon, chief operating officer and chief financial officer, will present an overview of Alfacell's financial performance for the fiscal second quarter 2008, ended January 31, 2008.

To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054. A replay of the call will be available until March 14. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 276752. A live Webcast and replay of the conference call will be available on Alfacell's Web site at http://www.alfacell.com.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:

David Schull or Wendy Lau Timothy Engel

Russo Partners Russo Partners

212-845-4271 212-845-4242

david.schull@russopartnersllc.com Timothy.Engel@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alfacell to Present at BIO InvestorForum 2007
2. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
3. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
4. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
5. CNS Response Announces Fiscal Third Quarter 2007 Results
6. Avitar Reports Third Quarter Financial Results for Fiscal 2007
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
11. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... innovators, engineers, and scientists from around the world, is pleased to announce the ... 22 and 23, 2017. This premier, online-only conference focused on the development and ...
(Date:2/22/2017)... Feb. 22, 2017 Aethlon Medical, Inc. (Nasdaq: ... a study that validated the ability of the Aethlon ... with increased mortality in immune-suppressed sepsis patients and also ... The objective of the study was to validate ... Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) ...
(Date:2/22/2017)... and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 /PRNewswire/ ... today announced its financial results for the fourth ... "Our annual 2016 financial results reflect continued growth ... exceeded $700 million," said Martine Rothblatt, Ph.D., United ... results strengthen our ability to develop and advance ...
(Date:2/21/2017)... PARK, CA (PRWEB) , ... February 21, 2017 ... ... of the VTX-1 Liquid Biopsy System , a fully automated benchtop system ... microfluidic technology. The VTX-1 is being launched at the Molecular Medicine Tri Conference ...
Breaking Biology Technology:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... 2017 Sensory Inc ., a ... for consumer electronics, and i nnerCore ... cybersecurity solutions, today announced a global partnership that ... worldwide to bolster security of data sensitive mobile ... authentication platforms they offer, innerCore now offers its ...
Breaking Biology News(10 mins):